<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175731</url>
  </required_header>
  <id_info>
    <org_study_id>2017037-QILU</org_study_id>
    <nct_id>NCT03175731</nct_id>
  </id_info>
  <brief_title>PPIs and Esophagogastric Variceal Bleeding in Cirrhotic Patients (PPIs: Proton Pump Inhibitors)</brief_title>
  <acronym>PPIs</acronym>
  <official_title>A Multicentre Randomized Controlled Study on the Effect of PPIs on Esophagogastric Variceal Bleeding in Cirrhotic Patients (PPIs: Proton Pump Inhibitors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanjing Gao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linyi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zibo City First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Liaocheng</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JINING No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at investigating the effect of PPIs on esophageal variceal bleeding in
      cirrhotic patients. Half of participants will receive PPI, while the other half will receive
      a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPIs can inhibit parietal cell H+/K+-ATPase and reduce secretion of gastric acid. PPIs can
      promote platelet aggregation and stabilize the formation of fibrin thrombosis by maintaining
      the high pH environment in the stomach and inactivating pepsin. The effect of PPIs on
      ulcerative upper gastrointestinal bleeding was confirmed but it is not clear whether PPIs is
      applicable in esophagogastric variceal bleeding whose etiology and bleeding position are
      different from ulcerative upper gastrointestinal bleeding. There is lack of consensus and
      sufficient evidences to support to use PPIs in esophagogastric variceal bleeding in cirrhotic
      patients universally. Nevertheless, the use of PPIs in patients with esophagogastric variceal
      bleeding is common.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rebleeding rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Rate of esophagogastric variceal rebleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>4 weeks</time_frame>
    <description>Prognosis of esophagogastric variceal bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The size of ulcers caused by endoscopic treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Follow-up after endoscopic treatment 2 weeks, 4 weeks respectively, and record the size of ulcers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole(or other PPIs) 40-80mg intravenously everyday before endoscopic treatment. And pantorazole(or other PPIs)tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 40-80mg intravenously everyday before endoscopic treatment.And placebo tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton Pump Inhibitors</intervention_name>
    <description>Pantoprazole(or other PPIs) 40-80mg intravenously everyday before endoscopic treatment. And pantorazole(or other PPIs)tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.</description>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 40-80mg intravenously everyday before endoscopic treatment.Placebo tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of cirrhosis

          -  Clinical diagnosis of esophagogastric variceal bleeding

        Exclusion Criteria:

          -  History of liver surgery, liver cancer or liver transplantation

          -  Gastrointestinal bleeding need emergency surgery

          -  Subject who incorporates peptic ulcer or gastroesophageal reflux disease which is
             indication for anti-acid therapy

          -  Subject who incorporates refractory diabetes

          -  Subject who incorporates esophageal ulcer before endoscopic therapy

          -  Subject who incorporates other systemic diseases can not be included, such as severe
             cardiopulmonary insufficiency, renal failure, nervous system diseases can not cope
             with

          -  Allergic to PPIs(proton pump inhibitors) or intolerable

          -  Pregnant, trying to become pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjing /A Gao, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital,Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YanJing Gao, PhD.MD</last_name>
    <phone>86-18560086087</phone>
    <email>gaoyanjing@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology,Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanjing Gao , PhD.MD</last_name>
      <phone>86-18560086087</phone>
      <email>gaoyanjing@sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Yanjing Gao</investigator_full_name>
    <investigator_title>Vice presidengt of Department of Gastroenterology of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Esophageal and gastric varices</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

